Publication Cover
Neurological Research
A Journal of Progress in Neurosurgery, Neurology and Neurosciences
Volume 45, 2023 - Issue 12
145
Views
0
CrossRef citations to date
0
Altmetric
Research Article

In-vivo anti-epileptic study of newly synthesized pregabalin derivatives based on docking studies

ORCID Icon, , , , , , & show all
Pages 1136-1143 | Received 25 Feb 2023, Accepted 06 Jul 2023, Published online: 26 Sep 2023
 

ABSTRACT

Objective

The goal of the present study is to examine pretreatment with Schiff bases and derivatives of pregabalin along with their metal (Zn and Cu) complexes on the severity of epilepsy, latency time, duration of convulsions, seizure score and survival rate in mice.

Methods

To achieve the goal, a molecular docking study of analogues was carried out on a specific molecular target, such as the alpha-2δ receptor (PDB ID: 6ND9); which revealed the significant binding affinity of the analogs to their respective target. Based on the docking information, all pregabalin derivatives were synthesized and in-vivo antiepileptic effect was confirmed by applying the PTZ model that prioritized the most crucial significant points responsible for biological activity.

Results

The test compounds markedly increased the latency of the first seizure and reduced the frequency of seizures throughout the body and frequent spinning and jumps. Additionally, treatment with pregabalin derivatives in mice that received PTZ significantly reduced the duration of seizures and seizure score. However, it increased the survival rate of the mice.

Discussion

Since the newly synthesized compounds were more active as compared to the parent drug in some respects; therefore, the expansion of the project can be planned to explore clinical side of the drugs in the future.

KEY POINTS

  • Docking studies of Schiff bases and derivatives of Pregabalin along with their Zn and Cu metal complexes

  • Pretreatment with Schiff bases and derivatives of pregabalin along with their metal (Zn and Cu)

  • PTZ Model of epilepsy

  • Observation of different parameters including; the severity of epilepsy, latency time, duration of convulsions, seizure score and survival rate in mice

  • Newly synthesized compounds were more active as compared to the parent drug

Disclosure statement

No potential conflict of interest was reported by the author(s).

Supplemental data

Supplemental data for this article can be accessed online at https://doi.org/10.1080/01616412.2023.2257440

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 421.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.